Dorsey Wright & Associates Acquires 12,535 Shares of Medpace Holdings, Inc. $MEDP

Dorsey Wright & Associates increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 126.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,420 shares of the company’s stock after purchasing an additional 12,535 shares during the period. Medpace accounts for about 2.7% of Dorsey Wright & Associates’ holdings, making the stock its 6th biggest holding. Dorsey Wright & Associates’ holdings in Medpace were worth $12,592,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Capital Fund Management S.A. grew its holdings in Medpace by 129.5% during the 3rd quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock worth $16,665,000 after acquiring an additional 18,287 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Medpace by 32.9% in the 3rd quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock valued at $15,702,000 after purchasing an additional 7,565 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Medpace by 9.9% in the 3rd quarter. Fisher Asset Management LLC now owns 137,746 shares of the company’s stock valued at $70,824,000 after purchasing an additional 12,399 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Medpace by 31.9% during the third quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock worth $9,458,000 after purchasing an additional 4,448 shares during the last quarter. Finally, Capital Impact Advisors LLC lifted its position in shares of Medpace by 31.7% during the third quarter. Capital Impact Advisors LLC now owns 26,995 shares of the company’s stock worth $13,880,000 after purchasing an additional 6,495 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of research reports. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Barclays cut their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Robert W. Baird reduced their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Royal Bank Of Canada decreased their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Finally, BMO Capital Markets lowered their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $467.08.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Performance

Medpace stock opened at $460.20 on Friday. The firm’s 50-day moving average is $453.33 and its 200-day moving average is $499.77. Medpace Holdings, Inc. has a 1 year low of $301.90 and a 1 year high of $628.92. The company has a market cap of $13.14 billion, a P/E ratio of 28.93, a PEG ratio of 2.32 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period in the previous year, the business posted $3.67 EPS. The company’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.